Goodwin Procter News Today

That there should be a limitation on a Government Employee cost recognized exercise of their rights, there needs to be guidance and that needs to be clearly indicated on what the employee can do. Let me say a couple of thank yous. I can name all the people that participated but particularly the aclu. I do not know if he knew what he would be eyeing into, six and a half years of fighting the government over my job. Lee rowland was the last attorney from the aclu representing me over the last coup...

Host the name of the book is the end of big how the internet makes david and goliath. The author is nicco mele and he joins us from boston. Mr. Mele before we get into the substance of your book if you could relate your personal experience to the book the end of big. Tesco i started my life as a Computer Programmer and ended up at the intersection of technology and politics in 2003. I joined howard deans president ial primary campaign. I joined very early in late april of 2003 and was on the cam...

Gina Nese, head of compliance and privacy at Align Technology, jumps at the chance to share new ideas and ways to innovate, including regarding emerging technologies like AI. Her work earned her recognition as CCO of the Year at the 2024 Excellence in Compliance Awards.

Akili to operate as wholly owned subsidiary of Virtual Therapeutics ...

Investegate announcements from PRTC's Akili Enters Into Merger Agreement

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented...

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy

Royalty Pharma plc (RPRX) announced Tuesday that it has acquired an interest in Agios Pharmaceuticals' (AGIO) royalty on Servier's vorasidenib for $905 million in upfront cash.

PRESS RELEASE ROYALTY PHARMA AND AGIOS PHARMACEUTICALS ENTER INTO VORASIDENIB ROYALTY AGREEMENT FOR $905 MILLION ...

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...